Inimmune

https://lnkd.in/eztvUVy6

Inimmune publishes positive proof of mechanism for TLR4 Agonist INI-2004 in Allergic Rhinitis Missoula, MT, July 30, 2024 Inimmune, a leading biotech company focused on the development of novel immunotherapies and vaccine adjuvants announced the publication of pre-clinical efficacy and safety data for INI-2004. “Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization” in Frontiers in Immunology on July 23, 2024 (https://lnkd.in/etGpSTiM). This research highlights the significant disease modifying impacts of INI-2004 in allergic disease following intranasal administration and describes the remarkable safety profile of this innovative treatment. INI-2004 is a fully synthetic allergen-agnostic immunotherapy that binds and activates TLR4. In a murine model of allergic rhinitis (AR), the disease modifying effect of intranasally administered INI-2004 was measured by a significant reduction in airway resistance, eosinophil influx, and cytokines involved in the pathogenesis of allergic rhinitis AR. These IND-enabling studies formed the basis for a recently completed Phase 1a/b clinical trial (NCT06038279) demonstrating that INI-2004 is safe and well tolerated over multiple administrations and improves nasal congestion in people suffering with allergic rhinits. This data demonstrates the utility of the mouse allergy model in evaluating TLR4 agonists as immunomodulatory drugs and proof of principle for the efficacy of INI-2004. Allergic rhinitis impacts over 400 million people globally and is one of the most common chronic diseases in the United States impacting 10-30% of adults and 40% of children. Safe and effective disease modifying treatments are still needed for allergic illness. “Treating the underlying disease is a critical step in stopping progression of atopy, especially for people who are poly-sensitized to multiple allergens. Inimmune is excited about this disease modifying novel treatment option for allergic rhinitis,” said Inimmune’s Chief Scientific and Strategy Officer, Dr. Jay Evans. About Inimmune Corporation Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics, adjuvants, and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity and cancer. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula, MT (USA). For more information on Inimmune’s research and development of novel immunotherapies, vaccine adjuvants, and delivery systems, please visit www.inimmune.com. Contact: Media Relations Inimmune Corporation Phone: (406)-541-5913 Email: info@inimmune.com

INIMMUNE ANNOUNCES FIRST CANCER PATIENT DOSED IN PHASE 1 CLINICAL STUDY USING THE IMMUNOTHERAPEUTIC INI-4001, A NOVEL TLR7/8 AGONIST (prnewswire.com)

SPI PHarma, Inc and Inimmune Corp. partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems

National Medicinal Chemistry Symposium

Inimmune Anounces Successful Phase I Clinical Results for Disease Modifying Allergy Treatment

December 28, 2023 Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on our innovative vaccine and adjuvant programs on Wednesday, December 29 at the World Vaccine Congress (West Coast) in Santa Clara, CA. Missoula, MT, December 28, 2023 - Inimmune, a leading clinical stage biotech company focused on the development of novel vaccines and immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at World Vaccine Congress (West Coast) (https://lnkd.in/eufm4_K). Innovative vaccine adjuvants and delivery technologies have demonstrated great progress for treatment and prevention of respiratory infections. Inimmune Corporation has an advanced portfolio of vaccine technologies and immunotherapy treatements focused in areas of high unmet need and global health prorities. "Inimmune has a remarkable pipeline of clinical stage vaccine adjuvants and is poised to change the landscape of technologies available for the prevention or treatment of respiratory diseases," said Alan Joslyn, CEO of Inimmune. "We are excited to have Dr. Evans represent Inimmune at World Vaccine Congress and provide an update on the innovative vaccine research being conducted at Inimmune.” The World Vaccine Congress will be held November 27-30 at the Santa Clara Convention Center (Santa Clara, California). The Congress will bring together industry experts in the areas of infectious disease vaccines, antiviral treatments, and cancer immunotherapy to showcase next-generation technologies.  About Inimmune: Inimmune Corp. (Missoula, MT) is a privately held clinical stage biotechnology company focused on the discovery and development of innovative immunotherapeutics, vaccine adjuvants, and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity and cancer.  Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula, MT. For more information on Inimmune's research and development of novel vaccine adjuvants and delivery systems, please visit www.inimmune.com. Contact: Media Relations Inimmune Corporation Phone: (406)-541-5913 Email: info@inimmune.com